Smarter. Stronger. Together: Educating Providers and Patients to Optimize the Use of Targeted Oral Therapies for HR+/HER2- Breast Cancer

Download All

Gain perspectives on strategies for optimizing use of CDK4/6 and PI3K inhibitors for HR+/HER2- breast cancer, including discussion on effective patient education about these targeted oral therapies! Learn from the experts with downloadable slides, commentaries, podcast, on-demand Webcast, and an Interactive Decision Support Tool providing personalized management recommendations for adverse events associated with CDK4/6 and PI3K inhibitors. Resources for your patients: https://www.smartpatients.com/resources/cco-breast-cancer

Matthew P. Goetz, MD
Sara Hurvitz, MD, FACP
Joyce O'Shaughnessy, MD

Downloadable Slidesets with ExpressPoints

Gain key clinical insights fast, with this short slideset from CCO on the optimal use of CDK4/6 and PIK3CA inhibitors for patients with HR+/HER2 breast cancer.  

Matthew P. Goetz, MD Sara Hurvitz, MD, FACP Joyce O'Shaughnessy, MD Released: March 9, 2021

Download these slides from a live Webinar to gain expert insight on the new and emerging data on the optimal use of CDK4/6 and PI3K inhibitors for patients with HR+/HER2 breast cancer.

Matthew P. Goetz, MD Sara Hurvitz, MD, FACP Joyce O'Shaughnessy, MD Released: March 5, 2021
Produced in collaboration with
Supported by an educational grant from
Lilly

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue